Coated Capsules Patents (Class 424/463)
  • COMPLEX FORMULATION FOR ORAL ADMINISTRATION COMPRISING PROBIOTIC FORMULATION AND 5-HT4 RECEPTOR AGONIST AND METHOD FOR THE PREPARATION THEREOF
    Publication number: 20120321709
    Abstract: Disclosed are a complex formulation for oral administration comprising probiotic formulation and 5-HT4 receptor agonist, and a method for the preparation thereof.
    Type: Application
    Filed: February 25, 2011
    Publication date: December 20, 2012
    Applicant: HANMI SCIENCE CO LTD
    Inventors: Jong Soo Woo, Jae Hyun Park, Yong Il Kim, Dong Ho Kim, Jun Young Choi
  • NOVEL GASTRORETENTIVE DOSAGE FORMS OF POORLY SOLUBLE DRUGS
    Publication number: 20120321706
    Abstract: Disclosed is a multi-layered gastroretentive dosage form for the controlled release of a poorly soluble drug or diagnostic in the stomach and gastrointestinal tract of a patient, folded into a capsule which disintegrates rapidly and the said multi-layered dosage form unfolds rapidly upon contact with the gastric juice. The mechanisms of the gastric retention are not dependent on and do not influence the materials and methods used in controlling the release of the said poorly soluble drug.
    Type: Application
    Filed: October 19, 2010
    Publication date: December 20, 2012
    Applicant: INTEC PHARMA LTD.
    Inventors: Suher Masri, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni, Nadav Navon
  • SILOXANE SURFACE-MODIFIED HYDROGEL AND HYDROGEL MICROPARTICLE COMPOSITIONS
    Publication number: 20120315329
    Abstract: Embodiments of the present invention relate generally to siloxane surface-modified hydrogel microparticles and pastes, methods for their preparation, and uses thereof for delivery of personal care and healthcare active ingredients, as well as agricultural active ingredients.
    Type: Application
    Filed: February 17, 2011
    Publication date: December 13, 2012
    Applicant: Dow Corning Corporation
    Inventors: Dongchan Ahn, James Thompson
  • CAPSULE OF COMPOUND DANSHEN DRIPPING PILLS
    Publication number: 20120315328
    Abstract: A capsule of compound danshen dripping pills are disclosed. The color of the capsule's shell is orange, yellow, green or blue and all of these colors are in the wavelength range of 446-620 nm.
    Type: Application
    Filed: February 17, 2011
    Publication date: December 13, 2012
    Applicant: Tasly Pharmaceutical Group Co., Ltd.
    Inventors: He Sun, Shuiping Zhou, Lanlan Zhang, Zhijuan Huang, Zhaohui Song
  • Bone semi-permeable device
    Patent number: 8304220
    Abstract: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.
    Type: Grant
    Filed: October 15, 2007
    Date of Patent: November 6, 2012
    Assignee: The Invention Science Fund I, LLC
    Inventors: Ed Harlow, Edward K. Y. Jung, Robert Langer, Eric C. Leuthardt, Lowell L. Wood, Jr.
  • CONTROLLED RELEASE ORAL PHARMACEUTICAL DOSAGE FORMS COMPRISING MGBG
    Publication number: 20120269891
    Abstract: Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.
    Type: Application
    Filed: January 19, 2012
    Publication date: October 25, 2012
    Applicant: PATHOLOGICA LLC
    Inventors: John McKearn, Jeremy Blitzer
  • Enhanced-diffusion capsule
    Patent number: 8287902
    Abstract: An ingestible capsule is provided for delivering medication to a subject. A capsule coating dissolves in a gastrointestinal tract of the subject. An inner core of the capsule has an outer surface associated therewith. The outer surface is disposed within the coating and expands when the coating dissolves. A medication is disposed on the outer surface, and the outer surface is configured such that the medication contacts an intestinal wall of the subject when the outer surface expands. Other embodiments are also provided.
    Type: Grant
    Filed: July 23, 2009
    Date of Patent: October 16, 2012
    Assignee: Rainbow Medical Ltd.
    Inventor: Yossi Gross
  • ORAL PHARMACEUTICAL COMPOSITION
    Publication number: 20120258167
    Abstract: The present application provides a method for treating or preventing Celiac disease. In one embodiment the method comprises administering to a patient in need thereof a composition comprising minicapsules, wherein the minicapsules comprise a steroid in a liquid, semi-solid or solid core, the minicapsules having release profiles to release the steroid in an active form at one or more sites along the gastrointestinal tract, the one or more sites comprising the proximal small intestine beginning at the duodenum and ending at the ileum. In a related embodiment the method comprises administering budesonide to a patient in need thereof in a pre-solubilised drug delivery format.
    Type: Application
    Filed: April 6, 2012
    Publication date: October 11, 2012
    Inventor: Ivan Coulter
  • COATED PHARMACEUTICAL CAPSULE DOSAGE FORM
    Publication number: 20120244216
    Abstract: Pharmaceutical compositions in unit dose form comprising a hard or soft capsule containing a fill consisting of one or more inert ingredients, and one or more coatings on the capsule, wherein at least one coating comprises at least one active pharmaceutical ingredient.
    Type: Application
    Filed: June 7, 2012
    Publication date: September 27, 2012
    Inventors: Manish S. SHAH, Ray J. Difalco
  • ENTERICALLY COATED CYSTEAMINE, CYSTAMINE AND DERIVATIVES THEREOF
    Publication number: 20120237599
    Abstract: The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.
    Type: Application
    Filed: February 17, 2012
    Publication date: September 20, 2012
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Ranjan Dohil, Jerry Schneider
  • PHARMACEUTICAL SOLID DOSAGE FORM
    Publication number: 20120231074
    Abstract: The present invention is directed to a solid dosage form comprising (i) a core comprising a benzimidazole; (ii) a separating layer comprising a water soluble polymer and glyceryl monostearate; and (iii) an enteric coating.
    Type: Application
    Filed: November 5, 2010
    Publication date: September 13, 2012
    Inventors: Angel Santanach-Delisau, Luis Soler Ranzani, Pierandrea Esposito
  • DEXLANSOPRAZOLE COMPOSITIONS
    Publication number: 20120231073
    Abstract: Premixes of dexlansoprazole with pharmaceutical excipients, processes for preparing premixes, pharmaceutical formulations containing the premixes, and their use in treatment of erosive esophagitis and heartburn associated with non-erosive gastroesophageal reflux disease.
    Type: Application
    Filed: May 18, 2012
    Publication date: September 13, 2012
    Applicants: DR. REDDY'S LABORATORIES, INC., DR. REDDY'S LABORATORIES LIMITED
    Inventors: Nagaraju Manne, Udaykumar Neelam, Sudhakar Reddy Baddam, Naveen Kumar Kolla, Venkata Nookaraju Sreedharala, Chandra Sekhar Veera Venkata Naga Bulusu
  • SCF Extract Containing Cardiac Glycoside
    Publication number: 20120219620
    Abstract: A supercritical fluid (SCF) extract of a cardiac glycoside-containing plant mass is provided. The extract can be included in a pharmaceutical composition containing an extract-solubilizing amount of solubilizer. Oleandrin is included within the extract when a cardiac glycoside-containing plant, such as Nerium oleander, is extracted by SCF extraction. The extract can also contain one or more other SCF extractable pharmacologically active agents. The composition can be used to treat a wide range of disorders that are therapeutically responsive to a cardiac glycoside.
    Type: Application
    Filed: March 12, 2012
    Publication date: August 30, 2012
    Applicant: Phoenix Biotechnology, Inc.
    Inventors: O.Cradell Addington, Feng Zhang, John J. Koleng
  • Bone delivery device
    Patent number: 8252570
    Abstract: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.
    Type: Grant
    Filed: September 12, 2007
    Date of Patent: August 28, 2012
    Assignee: The Invention Science Fund I, LLC
    Inventors: Ed Harlow, Edward K. Y. Jung, Robert Langer, Eric C. Leuthardt, Lowell L. Wood, Jr.
  • Oral controlled release dosage form
    Patent number: 8252327
    Abstract: A dosage form that provides a controlled release solid dosage form for the oral administration of a central nervous system stimulant, preferably methylphenidate hydrochloride.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: August 28, 2012
    Assignee: Andrx Pharmaceuticals, Inc.
    Inventors: Manesh Dixit, Chih-Ming Chen, Xiu-Xiu Cheng, Jianbo Xie
  • Treatment of Infection Using Single Chain Antibody Gene Therapy
    Publication number: 20120213848
    Abstract: A method for treating HIV and other intra-cellular parasites and toxins using intrabodies delivered to leukocytes.
    Type: Application
    Filed: November 16, 2011
    Publication date: August 23, 2012
    Inventor: Brian P. Hanley
  • DIMETHYL SULFOXIDE (DMSO) AND METHYLSULFONYLMETHANE (MSM) FORMULATIONS TO TREAT OSTEOARTHRITIS
    Publication number: 20120207827
    Abstract: Embodiments of the invention relate generally to the use of formulations comprising DMSO and MSM to treat arthritis (such as osteoarthritis), pain, inflammation, and/or degeneration. DMSO and MSM formulations are administered orally and/or topically in several embodiments and provide effective treatment of both chronic and acute symptoms of arthritis (e.g., osteoarthritis), pain, inflammation, and/or degeneration. Solid forms of DMSO are provided in several embodiments.
    Type: Application
    Filed: October 29, 2010
    Publication date: August 16, 2012
    Applicant: Abela Pharmaceuticals, Inc.
    Inventors: Colette Cozean, Jesse Cozean, Rodney Benjamin, Anthony Keller
  • NOVEL PARASITE THERAPY
    Publication number: 20120207826
    Abstract: There is disclosed herein a composition for treating extracellular parasitic infections, the composition comprising one or more of the following combinations: at least one quinolone or fluoroquinolone together with at least one tetracycline, iodoquinol, an azole or imidazole; or at least two agents selected from the group consisting of iodoquinol, thiazolidones, tetracycline, nitroimidazoles, cotrimoxazole and diloxanide furoate.
    Type: Application
    Filed: October 22, 2010
    Publication date: August 16, 2012
    Inventors: Thomas Julius Borody, Soledad Carsula
  • PHOSPHATE-BINDING MAGNESIUM SALTS AND USES THEREOF
    Publication number: 20120195964
    Abstract: The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and an enteric coating.
    Type: Application
    Filed: April 12, 2012
    Publication date: August 2, 2012
    Applicant: CYPRESS PHARMACEUTICAL, INC.
    Inventors: Robert L. Lewis, Charles E. Day
  • ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF MAMMALIAN DISEASES
    Publication number: 20120164075
    Abstract: The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and formulations for the treatment of a subject having or at risk for psychiatric and neurodegenerative diseases, infectious diseases, fertility disorders, osteoporosis, osteoarthritis, and/or cardiovascular diseases. Specifically, the present invention relates to compositions comprising endoxifen for use in the treatment of such disorders or predisposition to such disorders, for use in manufacture of medicaments for treating such disorders, and methods comprising use of such compositions in such treatments.
    Type: Application
    Filed: May 21, 2010
    Publication date: June 28, 2012
    Applicant: JINA PHARMACEUTICALS, INC.
    Inventors: Ateeq Ahmad, Shoukath M. Ali, Moghis U. Ahmad, Saifuddin Sheikh, Imran Ahmad
  • ABUSE RESISTANT DRUGS, METHOD OF USE AND METHOD OF MAKING
    Publication number: 20120164209
    Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.
    Type: Application
    Filed: February 29, 2012
    Publication date: June 28, 2012
    Applicant: INSPIRION DELIVERY TECHNOLOGIIES, LLC
    Inventors: Manish S. Shah, Ray Difalco
  • Pharmaceutical compositions for the coordinated delivery of NSAIDs
    Patent number: 8206741
    Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.
    Type: Grant
    Filed: May 16, 2005
    Date of Patent: June 26, 2012
    Assignee: POZEN Inc.
    Inventor: John R. Plachetka
  • ABUSE RESISTANT DRUGS, METHOD OF USE AND METHOD OF MAKING
    Publication number: 20120156277
    Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.
    Type: Application
    Filed: February 29, 2012
    Publication date: June 21, 2012
    Applicant: INSPIRION DELIVERY TECHNOLOGIES, LLC
    Inventors: Manish S. Shah, Ray J. Difalco
  • PROCESS FOR PREPARING OXYMORPHONE, NALTREXONE, AND BUPRENORPHINE
    Publication number: 20120156290
    Abstract: Methods are provided which include converting oripavine to other opiates, including converting oripavine to naltrexone, buprenorphine, 14-hydroxymorphinone and/or converting 14-hydroxymorphinone to oxymorphone. Purification and salt formation are optionally included.
    Type: Application
    Filed: February 28, 2012
    Publication date: June 21, 2012
    Applicant: PENICK CORPORATION
    Inventor: Bao-Shan HUANG
  • Regulation of T cell-mediated immunity by tryptophan
    Patent number: 8198265
    Abstract: A mechanism of macrophage-induced T cell suppression is the selective elimination of tryptophan and/or increase in one or more tryptophan metabolites within the local macrophage microenvironment. Studies demonstrate that expression of IDO can serve as a marker of suppression of T cell activation, and may play a significant role in allogeneic pregnancy and therefore other types of transplantation, and that inhibitors of IDO can be used to activate T cells and therefore enhance T cell activation when the T cells are suppressed by pregnancy, malignancy or a virus such as HIV. Inhibiting tryptophan degradation (and thereby increasing tryptophan concentration while decreasing tryptophan metabolite concentration), or supplementing tryptophan concentration, can therefore be used in addition to, or in place of, inhibitors of IDO.
    Type: Grant
    Filed: November 21, 2006
    Date of Patent: June 12, 2012
    Assignee: Medical College of Georgia Research Institute Inc.
    Inventors: David Munn, Andrew Mellor
  • THERAPEUTIC CALCIUM PHOSPHATE PARTICLES AND METHODS OF MAKING AND USING SAME
    Publication number: 20120128767
    Abstract: The present invention provides novel calcium phosphate nanoparticles suitable for efficient encapsulation of biologically active molecules. The invention further provides pharmaceutical compositions comprising these nanoparticles, as well as methods of making such nanoparticles and using them as carriers for therapeutic delivery of biologically active macromolecules.
    Type: Application
    Filed: May 1, 2009
    Publication date: May 24, 2012
    Inventors: William W. LEE, Feng LU
  • TREATMENT OF INSULIN RESISTANCE AND OBESITY BY STIMULATING GLP-1 RELEASE
    Publication number: 20120128770
    Abstract: The present invention relates to 1 or 2 C16-C18 acyl glycerol based compounds which are capable of activating G-protein coupled receptor 119 and thereby stimulate GLP-1 release. Compounds of the present invention are useful in the prophylaxis and/or treatment of metabolic disorders and complications thereof, such as, type 2 diabetes mellitus (T2DM), obesity, insulin resistance, and cardiovascular disease.
    Type: Application
    Filed: June 24, 2010
    Publication date: May 24, 2012
    Applicant: Kobenhavns Universitet
    Inventors: Harald S. Hansen, Thi Ai Diep, Jens Juul Holst, Mette Marie Rosenkilde, Niels Wellner Andersen
  • PHARMACEUTICAL COMPOSITION OF PEPTIDE DRUG AND ENZYME-INHIBITION COMPOUNDS
    Publication number: 20120121701
    Abstract: The invention relates to a method of co-administering a peptide or protein drug with an enzyme-resistant PGA-complexone compound orally so to mitigate enzyme attack in the gastrointestinal tract of an animal subject.
    Type: Application
    Filed: December 13, 2011
    Publication date: May 17, 2012
    Inventors: Hsing-Wen Sung, Kiran Sonaje, Hosheng Tu
  • PHARMACEUTICAL COMPOSITION FOR TREATING HCV INFECTIONS
    Publication number: 20120114751
    Abstract: The present invention relates to a granular pharmaceutical composition comprising an HCV protease inhibitor and at least one poloxamer.
    Type: Application
    Filed: November 8, 2011
    Publication date: May 10, 2012
    Inventors: Andreas Leiminer, Kai Lindenstruth, Dave Alan Miller, Emmanuel Scheubel, Navnit Hargovindas Shah
  • Methods of treating gastrointestinal disorders independent of the intake of food
    Patent number: 8173158
    Abstract: The present invention relates to a method of treating a gastrointestinal disorder by administering to a patient in need of treatment thereof a pharmaceutical composition, wherein said pharmaceutical composition can be administered to the patient independent of the intake of food.
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: May 8, 2012
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Ronald D. Lee, Majid Vakily, Darcy Mulford, Jing-Tao Wu, Stuart Atkinson
  • COMPOSITION FOR THE ADMINISTRATION OF POLYMERIC DRUGS
    Publication number: 20120100210
    Abstract: Provided are improvements in and relating to pharmaceutical compositions for oral administration of polymeric biological drug substances and to methods of treatment using such compositions. In particular, an oral and/or mucosal pharmaceutical composition is provided, said composition comprising an enteric-coated drug substance, and also comprising an enteric-coated oligouronate, wherein said drug substance is a polymeric biological drug substance.
    Type: Application
    Filed: March 23, 2010
    Publication date: April 26, 2012
    Applicant: NTNU TECHNOLOGY TRANSFER AS
    Inventors: Kurt Ingar Draget, Catherine Taylor
  • GASTRIC RESISTANT PHARMACEUTICAL OR NUTRACEUTICAL FORMULATION COMPRISING ONE OR MORE SALTS OF ALGINIC ACID
    Publication number: 20120093926
    Abstract: The invention relates to a gastric resistant pharmaceutical or nutraceutical composition, comprising a core, comprising a pharmaceutical or nutraceutical active ingredient and a gastric resistant coating layer onto the core, wherein the release of the pharmaceutical or nutraceutical active ingredient is not more than 15% under in-vitro conditions at pH 1.
    Type: Application
    Filed: April 13, 2011
    Publication date: April 19, 2012
    Applicant: Evonik Roehm GmbH
    Inventors: Shraddha Ashok Bodinge, Priyanka Bansilal Haksar, Seema Yashwant Gawde, Hemant Karbhari Pagar, Hans-Ulrich Petereit
  • AQUEOUS CARBONATED MEDIUM CONTAINING AN AMINO(METH)ACRYLATE POLYMER OR COPOLYMER
    Publication number: 20120087977
    Abstract: The invention relates to an aqueous medium containing an amino(meth)acrylate polymer or copolymer which is not soluble in demineralised water, characterized in that the medium has a content of an aqueous phase of at least 60% by weight and a content of up to 40% by weight of solids comprising the amino(meth)acrylate polymer or copolymer, whereby the aqueous phase is charged by a sufficient amount of carbon dioxide that effects the amino(meth)acrylate polymer or copolymer to be present in solute form in the medium. The aqueous medium may be used beneficially as a coating or binding solution for the spray coating or binding of pharmaceutical compositions or nutraceutical compositions or cosmetical compositions.
    Type: Application
    Filed: July 30, 2009
    Publication date: April 12, 2012
    Applicant: Evonik Roehm GmbH
    Inventors: Rosario Lizio, Michael Damm, Hans-Ulrich Petereit
  • Compositions For Treating Chronic Viral Infections
    Publication number: 20120082720
    Abstract: The present invention describes dietary compositions and methods of using such compositions to treat chronic viral infections, including hepatitis B and hepatitis C infections.
    Type: Application
    Filed: January 11, 2011
    Publication date: April 5, 2012
    Inventor: Sam Poon Ang
  • Enteric coating
    Publication number: 20120082721
    Abstract: The present invention refers to a dosage form comprising an enteric coating in a specific amount, and to the use of enteric coating compositions for preparing a dosage form. Furthermore, the present invention also relates to a process for the preparation of a solid oral dosage form.
    Type: Application
    Filed: May 28, 2010
    Publication date: April 5, 2012
    Applicant: H E X A L Aktiengesellschaft
    Inventors: Christian Buessing, Marco Marchesan, Andreas Krekeler
  • Pharmaceutical formulations
    Patent number: 8147871
    Abstract: The present invention is directed to novel pharmaceutically acceptable polymeric compositions suitable for melt extrusion and injection molding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected together in the assembled dosage form.
    Type: Grant
    Filed: March 11, 2005
    Date of Patent: April 3, 2012
    Assignee: Capsugel Belgium BVBA
    Inventors: Adrian Brown, Wayne M. Matthews, Daniel M. Margetson, Stephen Mark McAllister, Ronald K. Raby
  • Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs
    Publication number: 20120064156
    Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.
    Type: Application
    Filed: August 23, 2011
    Publication date: March 15, 2012
    Inventor: John R. Plachetka
  • Controlled release azithromycin solid dosages forms
    Patent number: 8124123
    Abstract: A solid dosage form for oral administration comprising azithromycin in an amount below that which causes gastrointestinal side effects, which dosage form is a controlled release dosage form.
    Type: Grant
    Filed: December 17, 2007
    Date of Patent: February 28, 2012
    Assignee: Dow Pharmaceutical Sciences, Inc.
    Inventors: Radhakrishnan Pillai, Pramod Sarpotdar, David W. Osborne, Gordon J. Dow
  • MODIFIED RELEASE COMPOSITIONS FOR DPP-IV INHIBITORS
    Publication number: 20120045509
    Abstract: The present invention refers to pharmaceutical composition comprising a DPP-IV inhibitor.
    Type: Application
    Filed: October 27, 2011
    Publication date: February 23, 2012
    Inventors: Bernd Michael Loeffler, Alexander MacDonald, Cynthia Rocha, Eric Worth
  • Blood brain barrier device
    Patent number: 8114647
    Abstract: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.
    Type: Grant
    Filed: October 18, 2007
    Date of Patent: February 14, 2012
    Assignee: The Invention Science Fund I, LLC
    Inventors: Ed Harlow, Roderick A. Hyde, Edward K. Y. Jung, Robert Langer, Eric C. Leuthardt, Lowell L. Wood, Jr.
  • COMPOSITIONS FOR THE TREATMENT OF GLUTEN INTOLERANCE AND USES THEREOF
    Publication number: 20120034299
    Abstract: The present invention provides compositions for use in the prophylaxis or treatment of a condition arising from gluten intolerance, the compositions including at least partially purified caricain (or a biologically active fragment, analogue or variant thereof) alone or in combination with other suitable enzymes including bromelain, and/or an intestinal extract, as herein described. The present invention also provides methods of using such compositions for the prophylaxis or treatment of a condition arising from gluten intolerance.
    Type: Application
    Filed: January 6, 2010
    Publication date: February 9, 2012
    Applicant: Glutagen Pty Ltd.
    Inventors: Teodor Stelmasiak, Hugh James Beatty Cornell
  • COATED DRUG DELIVERY FORMULATIONS
    Publication number: 20120027864
    Abstract: The invention relates generally to methods of making formulations for delivering biological agents to a patient. In one aspect, proliposomal drug-delivery systems for medicaments are provided. In another aspect, coated proliposomal formulations for poorly water soluble drugs, and methods for making the same, are provided. Certain embodiments of the present invention provide enhanced stability and bioavailability for pharmaceutical formulations.
    Type: Application
    Filed: October 7, 2011
    Publication date: February 2, 2012
    Applicant: WESTERN UNIVERSITY OF HEALTH SCIENCES
    Inventor: Guru V. BETAGERI
  • Compartmentalized dosage form
    Patent number: 8097278
    Abstract: The present invention provides a dosage form that prevents misuse of the medicament contained within. The dosage form contains an inactivating substance in combination with the medicament, wherein the two substances are separated by a permeable or semi-permeable partition. The partition becomes impermeable upon activation by a medical professional, thereby effectively sequestering the inactivating substance from the medicament and allowing for the intended administration of the medicament to the patient. Unless activated, however, the inactivating substance and medicament remain commingled in the dosage form, and any attempt to dispense the medicament before activation will result in the release of inactivated medicament.
    Type: Grant
    Filed: September 20, 2006
    Date of Patent: January 17, 2012
    Assignee: Purdue Pharma L. P.
    Inventor: Richard S. Sackler
  • Treatment Including Prebiotic Composition for use with Probiotics
    Publication number: 20120009256
    Abstract: Naturally occurring lecithins and/or oleic acid stimulate the growth and lactic acid producing activity of Lactobacillus and Bifidobacterium species of probiotic bacteria, and replace polysorbate 80 for those products. They can be used in naturally occurring form, or where they are to be combined with probiotics in a carrier, or they can be treated to yield a stable powdered form of these naturally oily compounds. They can be sold as combined prebiotic/probiotic formulations in the same carrier, or sold as separate dietary supplements, e.g., in capsule or tablet form, to be used with the probiotic formulation as desired.
    Type: Application
    Filed: May 30, 2011
    Publication date: January 12, 2012
    Applicant: MASTER SUPPLEMENTS, INC.
    Inventors: Randolph S. Porubcan, Sonja Lea Yonak
  • LEVETIRACETAM CONTROLLED RELEASE COMPOSITION
    Publication number: 20120003307
    Abstract: The present invention is concerned with controlled release compositions for oral administration comprising levetiracetam; and with processes of preparing such controlled release compositions.
    Type: Application
    Filed: November 26, 2008
    Publication date: January 5, 2012
    Applicant: RANBAXY LABORATORIES LIMITED
    Inventors: Namdev M. Kashid, Sunny Chopra, Sumit Madan, Vinod Arora
  • METHOD FOR ADDING SENSORY CONDITIONING CUES IN A PHARMACOTHERAPEUTIC REGIMEN
    Publication number: 20110311622
    Abstract: A method for administering pharmaceutical agents to a subject is provided. The method includes the steps of: a) providing a course of treatment for a subject, which course includes periodically administering an amount of medicine to the subject, which amount of medicine includes a dose of at least one active pharmacological agent (APA) and an amount of at least one non-active pharmacological agent (NPA), which NPA provides at least one non-visual sensory cue; and b) varying the dosage amount of the APA within the periodically administered amount of medicine, while the amount of the NPA contained within each periodically administered amount of medicine is provided at a level that maintains the sensory cue at a substantially constant level.
    Type: Application
    Filed: December 22, 2009
    Publication date: December 22, 2011
    Inventors: Joshua D. Levine, Robert A. Levine
  • PHARMACEUTICAL COMPOSITIONS AND METHODS OF DELVERY
    Publication number: 20110311621
    Abstract: The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent (such as CCK-8, octreotide), at least one salt of a medium chain fatty acid, a matrix forming polymer and a hydrophobic(lipophilic) medium. A surfactant may be included in the suspension. The pharmaceutical compositions may be formulated in a capsule or tablet for oral delivery. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed.
    Type: Application
    Filed: March 16, 2011
    Publication date: December 22, 2011
    Inventors: Paul Salama, Irina Karmeli, Shmuel Tuvia, Karen Marom, Oshrat Harush-Frenkel, Dana Gelbaum, Roni Mamluk, Fredric David Price, Steven Ronald Peikin
  • METHOD OF ADDING BOTANICAL AGENTS/DIETARY SUPPLEMENTS TO PHARMACEUTICAL AGENTS IN A PHARMACOTHERAPEUTIC REGIMEN
    Publication number: 20110305755
    Abstract: A method for administering an active pharmaceutical agent (APA) is provided that includes the steps of: a) providing a medicine having a dose of at least one APA and at least one active botanical agent (ABA) or dietary supplement; and b) dosing the APA within the medicine such that within each subsequent dose of the medicine, the amount of the APA decreases and the amount of the ABA increases, or remains the same, or decreases relative to an earlier amount. A trace of the APA may or may not remain in the pill toward the end of medicine application.
    Type: Application
    Filed: January 28, 2010
    Publication date: December 15, 2011
    Inventors: Joshua D. Levine, Robert A. Levine
  • Oral formulations of bipolar trans carotenoids
    Publication number: 20110300213
    Abstract: The subject invention relates to a variety of formulations of bipolar trans carotenoids including pharmaceutical compositions for oral delivery of a bipolar trans carotenoid comprising i) a bipolar trans carotenoid, ii) a cyclodextrin, and iii) a coating. The invention also relates to preparation of such formulations and their uses.
    Type: Application
    Filed: June 2, 2011
    Publication date: December 8, 2011
    Inventors: John L. Gainer, Robert Murray
  • ENTERIC FORMULATION OF DULOXETINE AND ITS CORE AND PREPRATION METHOD
    Publication number: 20110274750
    Abstract: An enteric formulation of duloxetine, its core and preparing method thereof are disclosed. The core comprises duloxetine or its salt and pharmaceutically acceptable excipients. The excipients include water-soluble hot melt materials selected from PEG, poloxamer, polyoxyl (40) stearate or their mixture. Based on the total weight of the core, the amount of water-soluble hot melt materials is 10%˜40% and the amount of duloxetine or its salt is 15˜60%. The core material is prepared by hot melt process. The enteric formulation comprises the core, a separating layer and an enteric layer.
    Type: Application
    Filed: November 4, 2009
    Publication date: November 10, 2011
    Applicant: SHANGHAI ZHONGXI PHARMACEUTICAL CORPORATION
    Inventors: Yunhui Ding, Siji Zheng